Fstar Therapeutics Stock Net Income
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess FStar Therapeutics' long-term financial health and intrinsic value.
FStar |
FStar Therapeutics Company Net Income Analysis
FStar Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current FStar Therapeutics Net Income | (31.28 M) |
Most of FStar Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, FStar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, FStar Therapeutics reported net income of (31.28 Million). This is 109.17% lower than that of the Healthcare sector and 144.66% lower than that of the Biotechnology industry. The net income for all United States stocks is 105.48% higher than that of the company.
FStar Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses FStar Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of FStar Therapeutics could also be used in its relative valuation, which is a method of valuing FStar Therapeutics by comparing valuation metrics of similar companies.FStar Therapeutics is currently under evaluation in net income category among its peers.
FStar Fundamentals
| Return On Equity | -0.61 | |||
| Return On Asset | -0.22 | |||
| Profit Margin | (2.11) % | |||
| Operating Margin | (1.62) % | |||
| Current Valuation | 98.23 M | |||
| Shares Outstanding | 21.98 M | |||
| Shares Owned By Insiders | 3.71 % | |||
| Shares Owned By Institutions | 44.90 % | |||
| Number Of Shares Shorted | 1.27 M | |||
| Price To Book | 2.13 X | |||
| Price To Sales | 5.47 X | |||
| Revenue | 21.17 M | |||
| Gross Profit | 21.17 M | |||
| EBITDA | (30.17 M) | |||
| Net Income | (31.28 M) | |||
| Cash And Equivalents | 35.57 M | |||
| Cash Per Share | 1.62 X | |||
| Total Debt | 9.61 M | |||
| Debt To Equity | 0.22 % | |||
| Current Ratio | 3.38 X | |||
| Book Value Per Share | 2.59 X | |||
| Cash Flow From Operations | (27.27 M) | |||
| Short Ratio | 1.88 X | |||
| Earnings Per Share | (1.83) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 84 | |||
| Beta | -0.35 | |||
| Market Capitalization | 156.51 M | |||
| Total Asset | 123.02 M | |||
| Z Score | 9.6 | |||
| Net Asset | 123.02 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in FStar Stock
If you are still planning to invest in FStar Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FStar Therapeutics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |